Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 8/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379477 | 1.00 | GSK3A (0.47) | GSK3AGSK3BCDK5CDK5R1KIF11 | |
| SCHEMBL379392 | 0.87 | ALDH1A1 (0.49) | GSK3AGSK3BCDK5CDK5R1PKM | |
| SCHEMBL379393 | 0.87 | ALDH1A1 (0.49) | GSK3AGSK3BCDK5CDK5R1PKM | |
| SCHEMBL379447 | 0.86 | ALDH1A1 (0.42) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL379446 | 0.86 | ALDH1A1 (0.42) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL378944 | 0.85 | GSK3A (0.42) | GSK3AGSK3BCDK5CDK5R1PKM | |
| SCHEMBL379327 | 0.85 | GSK3A (0.42) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL379326 | 0.85 | GSK3A (0.42) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL378945 | 0.85 | GSK3A (0.42) | GSK3AGSK3BCDK5CDK5R1PKM | |
| SCHEMBL379247 | 0.82 | GSK3A (0.45) | GSK3AGSK3BCDK5CDK5R1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968535-B2 | Antidiabetic agents; neurodegenerative disorders; mixture with immunosuppresants | DEVELOGEN ATKIENGESELLSCHAFT (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20080287423-A1 | Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders | EVOTEC INTERNATIONAL GMBH (DE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287423-A1 | Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders | IAPP, RNASE1, AMY2A | GSK3A 1819/4885GSK3B 2669/4885CDK5 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.